Spyre Therapeutics (SYRE) Total Liabilities (2015 - 2026)

Spyre Therapeutics' Total Liabilities history runs 12 years deep, the most recent figure standing at $93.1 million for Q1 2026.

• Quarterly Total Liabilities rose 6.85% year-over-year to $93.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $93.1 million (up 6.85% YoY) and the FY2025 annual result came in at $62.5 million, down 31.03% from the prior year.
• Total Liabilities was $93.1 million for Q1 2026 at Spyre Therapeutics, up from $62.5 million in the prior quarter.
• Across five years, Total Liabilities topped out at $253.6 million in Q2 2023 and bottomed at $18.8 million in Q1 2023.
• A 5-year average of $70.8 million and a median of $65.6 million in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2023 — Total Liabilities jumped 1024.5% — and 2024, when it tumbled 75.68%.
• Spyre Therapeutics' Total Liabilities stood at $20.8 million in 2022, then jumped by 251.69% to $73.3 million in 2023, then rose by 23.73% to $90.7 million in 2024, then plunged by 31.03% to $62.5 million in 2025, then surged by 48.92% to $93.1 million in 2026.
• Business Quant data shows SYRE's Total Liabilities at $93.1 million in Q1 2026, $62.5 million in Q4 2025, and $49.5 million in Q3 2025.